` IMU (Imugene Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

IMU
vs
S&P/ASX 300

Over the past 12 months, IMU has underperformed S&P/ASX 300, delivering a return of -76% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
IMU vs S&P/ASX 300

Loading
IMU
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
IMU vs S&P/ASX 300

Loading
IMU
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
IMU vs S&P/ASX 300

Loading
IMU
S&P/ASX 300
Add Stock

Competitors Performance
Imugene Ltd vs Peers

S&P/ASX 300
IMU
ABBV
AMGN
GILD
VRTX
Add Stock

Imugene Ltd
Glance View

Market Cap
104.2m AUD
Industry
Biotechnology

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

IMU Intrinsic Value
Not Available
Back to Top